Business Development

BD/partnering opportunities with biopharma/platform companies

  • Collaborate with biopharmaceutical companies in the development of “SELECT” companion diagnostics to assist with treatment decisions based on the efficacy and/or safety of a specific compound for specific population.
  • Identify new molecular diagnostic tests utilizing our SNAQ technology on ‘SELECT” platforms by translating a biomarker to a diagnostic.
  • Develop and leverage strategic collaborations with instrument and platform companies to increase SNAQ technology market penetration.
  • Strengthen development & applications for new oncology drug products and companion diagnostics by providing standardized data with “Intrinsic Quality Control”.

All inquires and communications regarding Accugenomics should be directed to Nick Lazaridis at nlazaridis@accugenomics.com.